Global Plasma Protease C1-Inhibitor Treatment Market Reached USD 4.38 Bn in 2026, Driven by the Rising Prevalence and Diagnosis of Hereditary Angioedema
Advancements in C1-Inhibitor Therapies and Growing Access to Preventive Treatment to Drive the Global Plasma Protease C1-Inhibitor Treatment Market to USD 8.06 Billion by 2033 at a 9.1% CAGR – Coherent Market Insights
Global Plasma Protease C1-inhibitor Treatment Market, by Drug Type (C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor Antagonist), by Dosage (Lyophilized and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at USD 4.38 Bn in 2026 and is expected to exhibit a CAGR of 9.1% during the forecast period (2026-2033), as highlighted in a new report published by Coherent Market Insights.
Plasma protease C1-inhibitor treatment market is expected to witness significant growth during forecast period, owing to increasing product approvals. For instance, in June 2017, CSL Behring, a global biopharmaceutical company, received the U.S. Food and Drug Administration for HAEGARDA (C1 Esterase Inhibitor Subcutaneous (Human)), the first and only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
Moreover, increasing focus of the major biopharmaceutical companies on development of C1-inhibitor therapies/ drugs is another factor contributing to growth of the Plasma protease C1-inhibitor treatment market. For instance, on October 31, 2019, Ionis Pharmaceuticals, Inc. initiated phase 2 clinical study to evaluate the clinical efficacy, safety, and tolerability of IONIS-PKK-LRx in participants with hereditary angioedema (HAE) type 1 (HAE-1), HAE type 2 (HAE-2), or HAE with normal C1-inhibitor (C1-INH) and to evaluate the effect of IONIS-PKK-LRx on plasma prekallikrein (PKK) and other relevant biomarkers.
Browse 32 Market Data Tables and 30 Figures spread through 186 Pages and in-depth TOC on “Million by 2033– Impact of Coronavirus (COVID-19) Pandemic
Global Plasma Protease C1-inhibitor Treatment Market, by Drug Type (C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor Antagonist), by Dosage (Lyophilized and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in the Global Plasma Protease C1-inhibitor Treatment Market, click the link below:
There are several U.S. FDA approved plasma protease C1-inhibitors for the treatment of HAE-C1-INH (Hereditary angioedema C1 esterase inhibitor (C1-INH)). These products include two human pdC1-INH concentrates – pasteurized, nanofiltered C1-INH (pnfC1-INH) concentrate (Berinert, CSL Behring GmBH, Marburg, Germany) and nanofiltered C1-INH (nfC1-INH) concentrate (Cinryze, ViroPharma Inc., PA, USA/Cetor, Sanquin Blood Supply, Amsterdam, The Netherlands), and recombinant C1-INH produced from transgenic rabbits (rhC1-INH), conestat alfa (Rhucin, Santarus Inc., CA, USA), Ruconest, (Pharming NV, Leiden, The Netherlands). Thus availability of such products in the market is contributing growth of the global plasma protease C1-inhibitor treatment market.
Key Takeaways of the Global Plasma Protease C1-inhibitor Treatment Market
- The global plasma protease C1-inhibitor treatment market is expected to exhibit a CAGR of 9.1% during the forecast period due to increasing number of clinical trial projects to evaluate the efficiency of the C1-inhibitors in various underlying diseases such as hereditary angioedema type I and II, C1 esterase inhibitor deficiency, and others.
- Lyophilized segment is expected to hold significant market share over the forecast period, owing to increasing practice of intravenous administration of drugs for the treatment of HAE and rising demand for intravenous/ lyophilized C1 esterase inhibitor drugs.
- Key players operating in the global plasma protease C1-inhibitor treatment market include CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.
Key News
- In April 2026, Intellia Therapeutics, Inc., biotechnology company reported positive Phase 3 results for lonvoguran ziclumeran, a one-time in-vivo CRISPR gene-editing therapy for hereditary angioedema. The company also initiated a rolling biologics licence application submission to the FDA. (Source: Intellia Therapeutics, Inc.)
- In June 2026, Octapharma is recruiting participants for a Phase III study evaluating OCTA-C1-INH, an intravenous human plasma-derived C1 esterase inhibitor, in hereditary angioedema caused by congenital C1-INH deficiency. The randomized, double-blind, placebo-controlled trial will assess efficacy and safety for treating acute attacks and preventing attacks before procedures. An estimated 124 participants aged two years and older will be enrolled across multiple international study sites, supporting broader treatment options for this rare disorder.
Contact Us